临床前 CRO 市场规模、份额、成长分析（按服务、按型号、按应用、按最终用户、按地区）- 产业预测 2025-2032

预计 2023 年全球临床前 CRO 市场规模将达到 64 亿美元，并从 2024 年的 70.1 亿美元增长到 2032 年的 146 亿美元，预测期内（2025-2032 年）的复合年增长率为 9.6%。

全球临床前合约组织 (CRO) 市场的成长主要得益于生物製药公司、医疗设备公司和政府研究机构日益增长的参与度，这些公司以合约方式利用 CRO 服务。慢性病和基因相关疾病的快速成长要求这些公司投入大量资金进行研究，以开发用于有效诊断和治疗的创新药物和设备。临床前 CRO 透过提供必要的研发解决方案，简化药物和设备开发流程，使这些公司能够专注于其核心业务。此外，对新型救命疗法的迫切需求也推动了对临床前研究的投资，巩固了 CRO 在药物开发和商业化策略中的关键作用。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

临床前 CRO 市场规模（依服务及复合年增长率） (2025-2032)

• 市场概览
• 生物分析和 DMPK 研究
  • 试管内ADME
  • 体内药物动力学
• 毒性测试
  • GLP
  • 非GLP
• 化合物管理
  • 製程研究与开发
  • 客製合成
  • 其他的
• 化学
  • 药物化学
  • 计算化学
• 安全药理学
• 其他的

临床前 CRO 市场规模（依型号及复合年增长率） (2025-2032)

• 市场概览
• 患者来源的类器官（PDO）模型
• 患者来源的异种移植模型

临床前 CRO 市场规模：按应用和复合年增长率（2025-2032）

• 市场概览
• 肿瘤学
• 神经病学
• 心臟病学
• 感染疾病
• 代谢紊乱
• 其他的

临床前 CRO 市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概览
• 製药和生物技术公司
• 政府和学术机构
• 医疗设备公司
• 其他的

临床前 CRO 市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Charles River Laboratories International, Inc.（USA）
• Labcorp Drug Development（USA）
• Eurofins Scientific（Luxembourg）
• ICON plc（Ireland）
• IQVIA（USA）
• Parexel International Corporation（USA）
• PPD（USA）
• Syneos Health（USA）
• Crown Bioscience（USA）
• Envigo（USA）
• Intertek Group plc（UK）
• SGS SA（Switzerland）
• MPI Research（USA）
• Worldwide Clinical Trials（USA）
• Inotiv, Inc.（USA）
• Jubilant Biosys Ltd.（India）

结论和建议

Global Preclinical CRO Market size was valued at USD 6.4 billion in 2023 and is poised to grow from USD 7.01 billion in 2024 to USD 14.6 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The growth of the global preclinical contract research organization (CRO) market is significantly fueled by the increasing engagement of biopharmaceutical companies, medical device firms, and government research agencies, who leverage CRO services on a contractual basis. The surge in chronic and gene-related diseases necessitates substantial investment from these companies in research aimed at the development of innovative drugs and devices for effective diagnosis and treatment. Preclinical CROs enable these organizations to concentrate on core activities by providing essential research and development solutions, thereby streamlining the drug and device creation process. Additionally, the urgent demand for new life-saving therapies is propelling investments in preclinical research, solidifying the crucial role of CROs in drug development and commercialization strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preclinical CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preclinical CRO Market Segments Analysis

Global Preclinical CRO Market is segmented by Service, Model, Application, End User and region. Based on Service, the market is segmented into Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology and Others. Based on Model, the market is segmented into Patient-Derived Organoid (PDO) Model and Patient-Derived Xenograft Model. Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical and Biotechnological Companies, Government and Academic Institutes, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Preclinical CRO Market

A significant catalyst for the growth of the global preclinical Contract Research Organization (CRO) market is the swift expansion of the biopharmaceutical industry. As biopharmaceutical companies increasingly venture into the development of innovative drugs, they are turning to CROs to manage essential preclinical testing activities, including drug efficacy evaluations and toxicity assessments. This growing reliance on outsourcing preclinical research functions not only enhances efficiency but also allows biopharma firms to focus on their core competencies. Consequently, the demand for preclinical CRO services is anticipated to rise substantially in the future, driven by this ongoing trend in the industry.

Restraints in the Global Preclinical CRO Market

One significant restraint in the Global Preclinical CRO market is the potential loss of management control during the development process when outsourcing preclinical testing. Biopharmaceutical companies that engage third-party CROs may find themselves with diminished oversight of their research activities. This dependency can hinder progress, as it may lead to delays, miscommunication, and inconsistent results. Consequently, a lack of direct management can restrict innovation and efficiency, ultimately affecting the overall success of drug development projects. These challenges underline the importance of careful selection and communication when collaborating with contract research organizations.

Market Trends of the Global Preclinical CRO Market

The Global Preclinical Contract Research Organization (CRO) market is experiencing a significant trend toward the integration of automation and artificial intelligence (AI), revolutionizing research operations. This transformation facilitates faster and more accurate outcomes, allowing for optimized data processing and predictive modeling in drug development. As AI-driven solutions become widespread, they not only enhance efficiency but also significantly reduce time and costs associated with preclinical studies. This trend underscores a broader shift within the industry towards embracing cutting-edge technologies, indicating that the market is poised for continued growth and innovation as organizations increasingly leverage these advancements to streamline their operations and improve research productivity.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Preclinical CRO Market Size by Service & CAGR (2025-2032)

• Market Overview
• Bioanalysis and DMPK studies
  • In vitro ADME
  • In-vivo PK
• Toxicology Testing
  • GLP
  • Non-GLP
• Compound Management
  • Process R&D
  • Custom Synthesis
  • Others
• Chemistry
  • Medicinal Chemistry
  • Computation Chemistry
• Safety Pharmacology
• Others

Global Preclinical CRO Market Size by Model & CAGR (2025-2032)

• Market Overview
• Patient-Derived Organoid (PDO) Model
• Patient-Derived Xenograft Model

Global Preclinical CRO Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Metabolic Disorders
• Others

Global Preclinical CRO Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical and Biotechnological Companies
• Government and Academic Institutes
• Medical Device Companies
• Others

Global Preclinical CRO Market Size & CAGR (2025-2032)

• North America (Service, Model, Application, End User)
  • US
  • Canada
• Europe (Service, Model, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Model, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Model, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Model, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Envigo (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intertek Group plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MPI Research (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Worldwide Clinical Trials (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotiv, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Biosys Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations